Skip to main content
SpringerLink
Log in

Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis

  • BITS AND BYTES
  • Published:
Journal of Cell Communication and Signaling Aims and scope

Abstract

Pirfenidone and nintedanib have been approved for idiopathic pulmonary fibrosis (IPF) due to their ability to statistically slow, over a year, the rate of decline in lung forced vital capacity (FVC), neither drug has been reported to have o positive effects on high-resolution computed tomography (HRCT) of the chest, symptoms, or quality of life. Moreover, pirfenidone and nintedanib have substantial gastrointestinal tolerability issues. Overall, these data highly suggest that novel therapeutic approached are needed. CCN2 has been shown to be a mediator of fibrosis in many preclinical models. Anti-CCN2 strategies are in clinical development for IPF, A recent study by Richeldi and colleagues described the recent Phase II clinical trial for FG-3019 in IPF, and the results were highly encouraging. This commentary contextualizes and summarizes these exciting findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Allen JT, Knight RA, Bloor CA, Spiteri MA (1999) mEnhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 21:693–700

    Article  CAS  Google Scholar 

  • Brenner MC, Krzyzanski W, Chou JZ, Signore PE, Fung CK, Guzman D, Li D, Zhang W, Olsen DR, Nguyen VT, Koo CW, Sternlicht MD, Lipson KE (2016) FG-3019, a human monoclonal antibody recognizing connective tissue growth factor, is subject to target-mediated drug disposition. Pharm Res 33:1833–1849

    Article  CAS  Google Scholar 

  • Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, Takehara K (1995) Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 105:280–284

    Article  CAS  Google Scholar 

  • Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, Grotendorst GR, Takehara K (1996) Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 106:729–733

    Article  CAS  Google Scholar 

  • Kinashi H, Falke LL, Nguyen TQ, Bovenschen N, Aten J, Leask A, Ito Y, Goldschmeding R (2017) Connective tissue growth factor regulates fibrosis-associated renal lymphangiogenesis. Kidney Int 92:850–863

    Article  CAS  Google Scholar 

  • Kleer CG (2016) Dual roles of CCN proteins in breast cancer progression. J Cell Commun Signal 10:217–222

    Article  Google Scholar 

  • Leask A (2019) A centralized communication network: Recent insights into the role of the cancer associated fibroblast in the development of drug resistance in tumors [published online ahead of print, 2019 Nov 7]. Semin Cell Dev Biol S1084–9521(18):30316–1. https://doi.org/10.1016/j.semcdb.2019.10.016

  • Lipson KE, Wong C, Teng Y, Spong S (2012) CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 5(Suppl 1):S24

    Article  Google Scholar 

  • Liu S, Shi-wen X, Abraham DJ, Leask A (2011) CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum 63:239–246

    Article  Google Scholar 

  • Makino K, Makino T, Stawski L, Lipson KE, Leask A, Trojanowska M (2017) Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis. Arthritis Res Ther 19:134

    Article  Google Scholar 

  • Parapuram SK, Thompson K, Tsang M, Hutchenreuther J, Bekking C, Liu S, Leask A (2015) Loss of PTEN expression by mouse fibroblasts results in lung fibrosis through a CCN2-dependent mechanism. Matrix Biol 43:35–41

    Article  CAS  Google Scholar 

  • Perbal B (2018) The concept of the CCN protein family revisited: a centralized coordination network. J Cell Commun Signal 12:3–12

    Article  Google Scholar 

  • Perbal B, Tweedie S, Bruford E (2018) The official unified nomenclature adopted by the HGNC calls for the use of the acronyms, CCN1-6, and discontinuation in the use of CYR61, CTGF, NOV and WISP 1-3 respectively. J Cell Commun Signal 12:625–629

    Article  Google Scholar 

  • Petrosino JM, Leask A, Accornero F (2019) Genetic manipulation of CCN2/CTGF unveils cell-specific ECM-remodeling effects in injured skeletal muscle. FASEB J 33:2047–2057

    Article  CAS  Google Scholar 

  • Richeldi L, Fernández Pérez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G (2019) Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med 27. https://doi.org/10.1016/S2213-2600(19)30262-0 [Epub ahead of print]

    Article  CAS  Google Scholar 

  • Sato S, Nagaoka T, Hasegawa M, Tamatani T, Nakanishi T, Takigawa M, Takehara K (2000) Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 27:149–154

    CAS  PubMed  Google Scholar 

  • Schild C, Trueb B (2004) Three members of the connective tissue growth factor family CCN are differentially regulated by mechanical stress. Biochim Biophys Acta 1691:33–40

    Article  CAS  Google Scholar 

  • Sternlicht MD, Wirkner U, Bickelhaupt S, Lopez Perez R, Tietz A, Lipson KE, Seeley TW, Huber PE (2018) Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab. Respir Res 19:14

    Article  Google Scholar 

  • Takigawa M (2018) An early history of CCN2/CTGF research: the road to CCN2 via hcs24, ctgf, ecogenin, and regenerin. J Cell Commun Signal 12:253–264

    Article  Google Scholar 

  • Tsang M, Quesnel K, Vincent K, Hutchenreuther J, Postovit LM, Leask A (2019) Insights into Fibroblast Plasticity: CCN2 Is Required for Activation of Cancer-Associated Fibroblasts in a Murine Model of Melanoma. Am J Pathol 11

  • Yeger H, Perbal B (2016) CCN family of proteins: critical modulators of the tumor cell microenvironment. J Cell Commun Signal 10:229–240

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Dentistry, University of Saskatchewan, 105 Wiggins Road, Saskatoon, SK, S7N 5E4, Canada

    Andrew Leask

Authors
  1. Andrew Leask
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Leask.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leask, A. Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis. J. Cell Commun. Signal. 13, 441–442 (2019). https://doi.org/10.1007/s12079-019-00542-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12079-019-00542-6

Keywords

Search

Navigation